Results 171 to 180 of about 24,887 (213)
Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF‐1 suppression to octreotide LAR in healthy volunteers [PDF]
British Journal of Clinical Pharmacology, 2015 To assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of octreotide subcutaneous (sc) depot, a novel octreotide ...
Johnsson, Markus +15 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Annals of Pharmacotherapy, 1997
In a limited number of case reports in infants, octreotide raised the blood glucose concentrations and decreased glucose requirements sufficiently to avoid pancreatectomy. This response occurs in the presence of frequent feedings and diazoxide therapy, and lasts from 1 month to greater than 5 years.
openaire +2 more sources
In a limited number of case reports in infants, octreotide raised the blood glucose concentrations and decreased glucose requirements sufficiently to avoid pancreatectomy. This response occurs in the presence of frequent feedings and diazoxide therapy, and lasts from 1 month to greater than 5 years.
openaire +2 more sources